Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
ComarJFBabeto de S-NakanishiAde OliveiraALMarques Nogueira WendtMBersani AmadoCAIshii IwamotoELet al
Dahms W
GSTs have emerged as a promising therapeutic target because specific isozymes are overexpressed in a wide variety of tumors and may play a role in the etiology of other diseases, including neurodegenerative diseases, multiple sclerosis, and asthma
To view a copy of this licence, visit About this article Cite this article Nilsen, J., Aaen, K.H., Benjakul, S
Its estimated around 24 million people in the United States, or 7% of the population, will take GLP-1 medications by 2035
Sourcing Matters: Why Purity is Non-Negotiable in 2026 We've touched on this, but it deserves its own section
US$ 25.28
US$ 23.33
US$ 20.55
